Meissa Vaccines has reported that its intranasal Covid-19 vaccine, MV-014-212, generated a robust nasal Immunoglobulin A (IgA) antibody response in seropositive and seronegative adults in Phase I clinical trial.
The live attenuated vaccine is built on the recombinant respiratory syncytial virus (RSV) AttenuBlock platform of Meissa.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It has been designed to be well-attenuated, genetically stable and optimised to offer strong and long-lasting immunity.
The latest initial results are from an interim analysis conducted on 49 subjects.
Of the doses ranging from 10^3-10^5 PFU analysed in the trial, the 10^5 PFU dose stimulated nasal IgA antibody levels that were in line with natural immunity to Covid-19 infection.
The safety data at all the tested dose levels of the vaccine showed MV-014-212 is greatly attenuated, without any infectious vaccine virus seen in trial subjects.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataFurthermore, no serious adverse events linked to the vaccine were observed so far.
Currently, the Phase I trial is underway enrolling subjects with full data anticipated next year.
Meissa Vaccines chief medical officer Robert Walker said: “The preliminary clinical data indicate a single, adjuvant-free, needle-free dose of Meissa’s Covid-19 intranasal vaccine can stimulate a nasal IgA antibody response similar to that seen after SARS-CoV-2 infection, with an important difference – safety.
“We will continue to advance Meissa’s Covid-19 intranasal vaccine in this Phase I clinical trial in adults, and we plan to evaluate it as a booster to complement injectable vaccines and initiate a Phase I paediatric study next year.”
The vaccine induced both mucosal and systemic antibodies and demonstrated greater protection against wild-type SARS-CoV-2 challenge in nonhuman primates in preclinical studies.
In addition, serum antibodies were found to neutralise wild-type SARS-CoV-2, as well as the Beta and Alpha variants of the virus.
